Calypte ZAHLEN

Calypte Biomedical Announces Second Quarter and Six-Month Financial Results

PLEASANTON, Calif., Aug. 12 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT) today announced financial results for the second quarter and six-months ended June 30, 2004. Revenue for the quarter increased 22% to $910,000, versus revenues of $749,000 for the comparable period in 2003. The net loss attributable to common stockholders for the quarter decreased 59% to $3.2 million, or $0.02 per common share, compared to a net loss of $7.9 million, or $0.72 per common share for the three months ended June 30, 2003. The net loss for the second quarter of 2004 and 2003 included $0.5 million and $4.1 million, respectively, in non-cash charges that were primarily related to the grants of common stock and options and warrants as compensation for services and non-cash interest expense related primarily to the accounting for Calypte's convertible debt financing instruments.

For the six months ended June 30, 2004, revenues increased 23% to $1.9 million, versus revenues of $1.5 million for the same period last year. The net loss attributable to common stockholders decreased by 49% to $7.3 million, or $0.05 per common share, compared to a net loss of $14.3 million, or $1.70 per common share for the six months ended June 30, 2003. The net loss for the six months ended June 30, 2004 and 2003 included $1.0 million and $7.7 million, respectively, in non-cash charges that were primarily related to the grants of common stock and options and warrants as compensation for services and non-cash interest expense related primarily to the accounting for Calypte's convertible debt financing instruments.

"We are pleased with the strides that we have taken in the development of our rapid test products this quarter. We have gained momentum and strength as we move forward in the execution of our business plan," stated Richard George, President and CEO. "We remain committed to and focused on the introduction of our rapid HIV-1/2 diagnostic tests to the international markets. In pursuit of this objective, we have recently completed the second phase of our initial international field trials of our urine, blood and oral fluid rapid HIV tests in Thailand. We believe that the studies validate the technology for our suite of rapid test products, and we plan to move all three assays into manufacturing sequentially. We look forward to completing the development of our rapid tests and the shifting of our focus to commercializing our rapid test products," Dr. George concluded.

Calypte management will host a conference call today to discuss and answer questions regarding the Company's second quarter financial results as well as provide an update on the Company's current activities at 11:00 a.m. Eastern Time.

The call can be accessed in the U.S. by dialing 800-435-1261 and outside of the U.S. by dialing 617-614-4076 and entering conference identification number 37168134. The conference call will also be webcast live at http://www.calypte.com . An audio replay of the call will be available until August 24, 2004, beginning approximately 1 hour after the conference call ends, by dialing 888-286-8010 in the US, or 617-801-6888 from outside of the U.S. The conference identification number is 60270956. The replay will also be available on http://www.calypte.com .

About Calypte Biomedical:

Calypte Biomedical Corporation, headquartered in Pleasanton, California, is a public healthcare company dedicated to the development and commercialization of in vitro diagnostic tests, primarily for the detection of antibodies to Human Immunodeficiency Virus (HIV), and other sexually transmitted and infectious diseases. Calypte's currently marketed laboratory-based tests include an enzyme immunoassay (EIA) HIV-1 antibody screening test and an HIV-1 antibody western blot supplemental test, the only two FDA-approved HIV-1 antibody tests for use on urine samples, as well as an FDA-approved serum HIV-1 antibody western blot supplemental test. Calypte is actively engaged in developing new test products for the rapid detection of HIV and other infectious diseases. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser-developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other infectious diseases may make important contributions to public health.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, demand for the Company's products, the Company's success in designing and developing products, the Company's research and development costs, the length of development and product acceptance cycles, the amount that the Company invests in new business opportunities and the timing of those investments, competition, the degree to which the Company enters into commercial agreements and strategic transactions and maintains and develops commercial relationships, foreign exchange risks, world events, international growth and expansion and changes in laws and regulations. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2003 and its subsequent filings with the SEC.


                CALYPTE BIOMEDICAL CORPORATION AND SUBSIDIARIES

                     CONSOLIDATED STATEMENTS OF OPERATIONS
                     (in thousands, except per share data)
                                   Unaudited

                                       Three Months Ended  Six Months Ended
                                             June 30,           June 30,
                                           2004     2003     2004      2003

    Revenues:
      Product sales                        $910     $749   $1,881    $1,533

      Cost of product sales               1,013    1,550    2,993     2,965
        Gross Margin (Loss) on product
         sales                             (103)    (801)  (1,112)   (1,432)

    Other operating expenses:
      Research and development costs        573      335    1,114       649
      Selling, general and
       administrative costs               2,539    5,609    4,736     9,619

        Total other operating expenses    3,112    5,944    5,850    10,268

          Loss from operations           (3,215)  (6,745)  (6,962)  (11,700)

    Interest income (expense)
     (primarily non-cash for both
     periods)                              (233)  (1,258)    (530)   (2,772)
     Minority interest in consolidated
      joint venture                         190        -      190         -
    Other income (expense)                   14       79       19       207

          Loss before income taxes       (3,244)  (7,924)  (7,283)  (14,265)

    Income taxes                              -        -       (2)       (2)

          Net loss                       (3,244)  (7,924)  (7,285)  (14,267)

    Less dividends on mandatorily
     redeemable Series A
      preferred stock                         -      (30)       -       (60)

    Net loss attributable to common
     stockholders                       $(3,244) $(7,954) $(7,285) $(14,327)

    Net loss per share attributable to
     common stockholders
      (basic and diluted)                $(0.02)  $(0.72)  $(0.05)   $(1.70)

    Weighted average shares used to
     compute net
      loss per share attributable to
       common stockholders
      (basic and diluted)               148,282   11,079  142,481     8,432


                 CALYPTE BIOMEDICAL CORPORATION AND SUBSIDIARY

                        CONSOLIDATED BALANCE SHEET DATA
                                (in thousands)
                                   Unaudited
                                                   June 30,     December 31,
                                                       2004            2003

    Cash and cash equivalents                        $6,036          $5,084
    Working capital                                   5,761           2,865
    Total Assets                                     11,869           9,517
    Convertible notes and debentures, net of
     discount                                           120             868
    Other long term liabilities                         108             157
    Minority Interest in joint venture                 (133)             57
    Mandatorily redeemable Series A
     preferred stock                                  2,756           2,696
    Total stockholders' equity                        4,688             917

    Company Contact:
    Richard Brounstein, CFO
    (925) 730-7200
    Email:  rbrounstein@calypte.com

    Investor Relations Contact:
    Tim Clemensen,
    Rubenstein Investor Relations
    Phone: 212-843-9337
    Email:  tclemensen@rubensteinir.com

SOURCE  Calypte Biomedical Corporation
   -0-                             08/12/2004
   /CONTACT:  Richard Brounstein, CFO of Calypte Biomedical Corporation,
+1-925-730-7200, rbrounstein@calypte.com; Investor Relations - Tim Clemensen,
Rubenstein Investor Relations, +1-212-843-9337, tclemensen@rubensteinir.com,
for Calypte Biomedical Corporation/
   /Web site:  http://www.calypte.com /
   (CYPT)

CO:  Calypte Biomedical Corporation
ST:  California, Thailand
IN:  BIO HEA MTC OTC
SU:  ERN CCA

EA
-- NYTH027 --
7219 08/12/2004 08:00 EDT http://www.prnewswire.com


 

posten? ;O)  

....sooo schwaz siehts ja garnet aus!

 

berühmten Großaufträge.Vielleicht klappts ja.Bist schon länger investiert oder überlegst noch?Ist schwierig momentan.  

EWIG dabei und habe auch sehr gute Gewinne gemacht! Jatzt habe ich allerdings nur noch einen "Scherbenhaufen" liegen! Der tut auch garnimmer weh! Also ich KANN nur noch gewinnen :-)
Hatte mich aus den Diskussionen der letzten Zeit rausgehalten, da viel zu viel BULLSHIT gepostet wurde! Das war mich echt zu blöd.  

an den "blöden" diskussionen selbst teilnahm.naja.mal schaun wie es weiter geht.  

zahlen dem ein oder anderen nichtwissenden in den staaten als hervorragend verkauft werden. ihr solltet zu den zahlen mal die anhänge aus den filings posten, woraus hervorgeht, dass die zukunft von caly sehr vage ist und das man unbedingt neues kapital beschaffen muß...  

There can be no assurance that subsequent additional financing, if and as necessary, will be available, or if it is available, that it would be on acceptable terms. The terms of an additional financing could involve a change of control and/or require stockholder approval, or could potentially trigger anti-dilution clauses that are contained in existing financing agreements. We would or might be required to consider strategic opportunities, including merger, consolidation, sale or other comparable transaction, to sustain our operations. We do not currently have any agreements in place with respect to any such new strategic opportunity, and there can be no assurance that any such opportunities will be available to us on acceptable terms, or at all. If additional financing is not available when and if required or is not available on acceptable terms, or we are unable to arrange a suitable strategic opportunity, we will be in significant financial jeopardy and we may be unable to continue our operations at current levels, or at all.  

Our operating cash burn rate for the three and six months ended June 30, 2004 and for the year ended December 31, 2003 averaged approximately $1.1 million per month. Our cash balance at June 30, 2004 reflects the remainder of the approximately $8.8 million in net proceeds we received from our May 2004 private placement. Additionally, we received approximately $1.4 million in net proceeds from our July 2004 private placement and have a commitment for approximately $3.6 million from the issuance of 9% promissory notes through December 31, 2004 under the amended Marr Credit Facility, should our Board of Directors unanimously approve the issuance of one or more such notes before the commitment period expires. In the absence of any unanticipated material costs and expenses that are not factored into our cash flow projections, we believe that these resources will be adequate to sustain our operations at expected levels through 2004, during which time we expect to pursue the commercialization of our rapid HIV test products currently in development. Alternatively, we may seek to raise additional capital; however, we may not be able to obtain additional financing on acceptable terms, or at all.

 

dann gehe ich mal auf das Niveau:

joelu, scheinst recht neu hier zu sein! Warscheinlich genauso neu wie "am Markt".

O.g. Zahlen sind nicht aufgewärmt sonder frisch. Fakt ist, das bei Caly zuletzt sehr viel "schlecht" gelaufen ist und dass auch Caly "Mist" gebaut hat! Jedoch ist die Branche in der wir uns hier bewegen a) sehr eng b) absolut zukunftsorientiert.

Ich mag es einfach nicht wenn kl. dumme Leute (jeder soll sich seinen Schuh anziehen) Unternehmen wie z.B. Calypte schlecht machen. Scheiss Management, Scheiss Vertrieb, ect. ect.! Genau diese kleinen dummen Leute würden in dem Marktsegment nicht einen Tag den Kopf über Wasser halten können. Es ist schier unglaublich was Caly in den letzten 2,5 Jahren ereicht hat. NEIN es hat sich noch nicht in Umsatzzahlen wiedergespiegelt, aber sie haben ÜBERLEBT!!! Sie sind kurz vor dem Ernten der Früchte das steht fest! Wenn die es jetzt noch schaffen ein weiteres Jahr durchzuhalten (JAAA das haben Sie bisher auch geschafft und davor sollte ein jeder den Hut ziehen) wird der Umsatz = Gewinn auch kommen.

Div. kleine dumme Leute lesen irgendwo mal was von "Caly braucht dringend Geld" und machen sofort die Türen für den Insovenzverwalter auf! LEUTE, dann könnten 85% unserer deutschen Unternehmen zu machen!

Für Caly sehe ich rel. postitiv in die Zukunft! Das Management hat sehr viel dazu gelernt und die Firma steht (WISSENSTECHNISCH) sehr sehr gut da! Wissen ist in schlechten Zeiten FAST wichtiger als Geld!!

So, ich werde mich aus weiteren Diskussionen mit kleinen dummen Leuten heraushalten, da man "nicht über den Tellerrand blickende" NICHT mit Argumenten kommen kann! Die sind eher wie die kleinen Mücken die immer gegen die Scheibe fliegen und einfach nicht raffen (fehlende Intelligenz) das da eine GLASSCHEIBE ist!!

Euer stet`s neutraler REALIST

realer  

 

um es mit deinen worten zu sagen:

"So, ich werde mich aus weiteren Diskussionen mit kleinen dummen Leuten heraushalten, da man "nicht über den Tellerrand blickende" NICHT mit Argumenten kommen kann! Die sind eher wie die kleinen Mücken die immer gegen die Scheibe fliegen und einfach nicht raffen (fehlende Intelligenz) das da eine GLASSCHEIBE ist!!"



...Our longer-term liquidity and capital requirements are dependent on factors similar to those which impact our current liquidity and capital resource considerations and which will be critical in validating our business model during 2004 and 2005. Consequently, we cannot predict the adequacy of our capital resources on a long-term basis. There can be no assurance that we will achieve or sustain profitability or positive cash flows in the future. In addition, there can be no assurance that subsequent additional financings, if and as necessary, would be available to us on a timely basis, or that if it is available, that it would be on acceptable terms, if at all.  

 

 

 

Das müssen die Schreiben! Mann mann mann! Das ist ne reine Absicherung. Ist doch logisch!
Das ist so als würdest Du eine rechtlich WASSERDICHTE Bedienungsanleitung für eine Mikrowelle schreiben. Dort müsstest Du auch ALLES reinschreiben was man NICHT in eine Mikrowelle tun darf!  

 

 

Go Tony Go

Today is the big day!!!!!

Need to top last years pump to get skipper back to even.

The "insiders" are counting on you. (80,000,000 worth)

Don't let us down. Give us your best used car salesman spiel.

Lets hear about sales percentages over 2nd quarter of last year not actual numbers or the fact the sales have been declining for last two quarters or the fact that total sales are still less than 25% of expenses of CYPT. Less than a million in sales(even less than first quarter) and over $ 4,000,000 in expenses.

Lets hear about licenses received but don't mention all the licenses that are still needed that have not been received. Just like you have done for the last 9 months say that these licenses are "in the works" or "in Negotiation" and should be in place "soon".

Tell everyone that the amount owed royalty holders has been reduced by 25%. Don't mention the fact that despite $ 23,000,000 in new cash from discounted stock sales in last year these amounts have not been paid in full.

Be sure and mention that the SEC has said case closed on last years PRs and tell everyone that there was no punishment. Leave off "at this time" as this might confuse someone.

Don't mention fact that the distributor for the Western Blot serum test (which is 36% of CYPT's revenue) has quit distributing and CYPT has yet to find a replacement.

Hints to drop: (you can always call them forward looking statements when they don't come true just as in the past).

AMEX listing in "near future"
Magic to finally come on board with AMEX
"Imminent" WHO approvals for CYPT's products
"Imminent" FDA IDE on CYPT rapid urine test
Thai facility will have rapid serum in production "shortly"
Incidence test will be sold "soon".
Sales of rapid test in "2004"
Sales 0f rapid test in Chinese market to start "soon".

You know the drill Tony you have done it dozens of times.

 

zu unseren -6 SchwarzenSterne Thread  

 

Last 10 trades


Time  Price  Volume  Exchange  Info


09:40:58    0.405 2400 OTCBB  
09:33:08    0.415 12000 OTCBB  
09:32:42    0.405 2000 OTCBB  
09:31:36    0.405 3600 OTCBB  
09:30:06    0.415 300 OTCBB  
N/A    N/A N/A OTCBB  
N/A    N/A N/A OTCBB  
N/A    N/A N/A OTCBB  
N/A    N/A N/A OTCBB  
N/A    N/A N/A OTCBB
 

hauen die leute nicht vom hocker, gell??? vielelicht doch aufgewärmt und vor 4 tagen schon veröffentlicht??? oder haben alle anderen außer euch den besonderen charme diese zahlen nicht erkannt? (lach, gröhl)

noch was RT gefällig?

Last 10 trades


Time  Price  Volume  Exchange  Info


09:51:22    0.400 5000 OTCBB  
09:47:18    0.400 2600 OTCBB  
09:47:05    0.400 2400 OTCBB  
09:45:58    0.400 2000 OTCBB  
09:44:57    0.400 2600 OTCBB at Bid
 

Diese Woche hatte freenet seine Zahlen bekannt gegeben! Diese waren was die Kundengewinnung betrifft sehr gut! Lediglich weil einzelne ERWARTUNGEN nicht ereicht wurden und der Markt sehr umkämpft ist brach der Kurs um ganze 25% ein!

Na und?? Das wird/kann bei Caly jetzt hier und heute auch passieren!

Das sind halt die "nitüberdentellerrandgugger"  

ich gucke nie über den rand. du hast den wahren durchblick. die zahlen scheinen ja auch keinen sonderlich zu interessieren...bei soviel umsatz

caly mit freenet zu vergleichen grenzt schon an unwissen...

Last 10 trades


Time  Price  Volume  Exchange  Info


10:00:07    0.400 2600 OTCBB  
10:00:04    0.400 2400 OTCBB  
09:56:05    0.400 2600 OTCBB  
09:55:42    0.400 2400 OTCBB